Tellus Therapeutics

Pioneering myelination therapy for neonatal white matter injury

Built from URL

HealthcarePharmaceuticals & MedicineNeuroscienceBiotechDrug DiscoveryPediatric CarePediatrics

MassChallengeBoston 2019 (finalists)

AboutBuilt from URL

Tellus Therapeutics develops regenerative medicine therapies for premature infants facing brain and gut injuries in the NICU. The company is pioneering the first myelination therapy for neonatal white matter injury and establishing a platform for treating diseases of myelination and inflammation from infancy to adulthood.

ProblemBuilt from URL

See something off about this company?